作者
Thomas Bachelot, Céline Bourgier, Claire Cropet, Isabelle Ray-Coquard, Jean-Marc Ferrero, Gilles Freyer, Sophie Abadie-Lacourtoisie, Jean-Christophe Eymard, Marc Debled, Dominique Spaëth, Eric Legouffe, Djelila Allouache, Claude El Kouri, Eric Pujade-Lauraine
发表日期
2012/8/1
期刊
Journal of Clinical Oncology
卷号
30
期号
22
页码范围
2718-2724
出版商
American Society of Clinical Oncology
简介
Purpose
Cross-talk between signal transduction pathways likely contributes to hormone resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian target of rapamycin, has restored sensitivity in endocrine-resistance models and shown anticancer activity in early-phase mBC clinical trials. This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs).
学术搜索中的文章
T Bachelot, C Bourgier, C Cropet, I Ray-Coquard… - Journal of Clinical Oncology, 2012